The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | Modalities for testing metastatic colorectal cancer targets
John Strickler, MD, Duke University, Durham, NC, details how the standard practice for gastrointestinal (GI) cancer diagnosis in the USA involves next generation sequencing (NGS). This involves testing targets concurrently, including MSI, BRAF, KRAS, NRAS and HER-2. Other testing methods may involve immunohistochemistry (IHC) or circulating tumor DNA (ctDNA) for select targets. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
